Exposed: 10 CENT Crypto to Explode April 20th?

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Stephanie S. Okey net worth and biography

Stephanie Okey Biography and Net Worth

Director of PTC Therapeutics

Ms. Okey most recently served as the Senior Vice President, Head of North America, Rare Diseases and U.S. General Manager, Rare Disease Business Unit at Genzyme. Ms. Okey brings nearly three decades of biotech experience, launching and commercializing rare and orphan disease products, as well as large market products. During her time at Genzyme, Ms. Okey oversaw 500 employees and was responsible for six business units: Gaucher Disease and MPS1, Fabry Disease, Pompe and Neuromuscular Diseases, Cardiovascular Diseases, Endocrine Diseases and Leukine and Immunologic Diseases. She has successfully launched 13 therapeutic agents, 9 of which were in the orphan disease space. Ms. Okey is highly knowledgeable about complex approval processes, healthcare stake holder systems and markets. Prior to her 19-year tenure at Genzyme, Ms. Okey held roles at MedImmune, Genentech and Bristol-Myers Squibb.

What is Stephanie S. Okey's net worth?: The estimated net worth of Stephanie S. Okey is at least $165,600.00 as of March 28th, 2024. Ms. Okey owns 6,000 shares of PTC Therapeutics stock worth more than $165,600 as of April 26th. This net worth approximation does not reflect any other assets that Ms. Okey may own. Learn More about Stephanie S. Okey's net worth.
How do I contact Stephanie S. Okey?: The corporate mailing address for Ms. Okey and other PTC Therapeutics executives is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. PTC Therapeutics can also be reached via phone at (908) 222-7000 and via email at [email protected]. Learn More on Stephanie S. Okey's contact information.
Has Stephanie S. Okey been buying or selling shares of PTC Therapeutics?: Stephanie S. Okey has not been actively trading shares of PTC Therapeutics within the last three months. Most recently, Stephanie Okey sold 2,296 shares of the business's stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $51.62, for a transaction totalling $118,519.52. Following the completion of the sale, the director now directly owns 1,867 shares of the company's stock, valued at $96,374.54. Learn More on Stephanie S. Okey's trading history.
Who are PTC Therapeutics' active insiders?: PTC Therapeutics' insider roster includes Neil Almstead (Insider), Mark Boulding (VP), Emily Hill (CFO), Allan Jacobson (Director), Matthew Klein (COO), Stephanie Okey (Director), Eric Pauwels (Insider), Stuart Peltz (CEO), Dawn Svoronos (Director), and Christine Utter (CAO). Learn More on PTC Therapeutics' active insiders.
Are insiders buying or selling shares of PTC Therapeutics?: During the last twelve months, PTC Therapeutics insiders bought shares 1 times. They purchased a total of 7,700 shares worth more than $198,737.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 15 times. They sold a total of 69,128 shares worth more than $2,672,029.04. The most recent insider tranaction occured on April, 19th when CEO Matthew B Klein sold 3,361 shares worth more than $83,655.29. Insiders at PTC Therapeutics own 5.3% of the company. Learn More about insider trades at PTC Therapeutics.
Information on this page was last updated on 4/19/2024.

Stephanie S. Okey Insider Trading History at PTC Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/9/2022	Sell	2,296	$51.62	$118,519.52	1,867
8/13/2021	Sell	1,650	$40.06	$66,099.00	963
12/8/2020	Sell	687	$62.52	$42,951.24	963

Stephanie S. Okey Buying and Selling Activity at PTC Therapeutics

PTC Therapeutics Company Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Today's Range

Now: $27.60

$25.67

$28.09

50 Day Range

MA: $28.10

$24.69

$31.95

2 Week Range

Now: $27.60

$17.53

$59.84

Volume

86,284 shs

Average Volume

951,861 shs

Market Capitalization

$2.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.67

Exposed: 10 CENT Crypto to Explode April 20th?

From True Market Insiders | Ad